Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P36897: Variant p.Arg487Pro

TGF-beta receptor type-1
Gene: TGFBR1
Feedback?
Variant information Variant position: help 487 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Proline (P) at position 487 (R487P, p.Arg487Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and hydrophobic (P) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LDS1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 487 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 503 The length of the canonical sequence.
Location on the sequence: help MAKIMRECWYANGAARLTAL R IKKTLSQLSQQEGIKM The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         MAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM

Mouse                         MAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM

Rat                           MAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM

Pig                           MAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM

Bovine                        MAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 34 – 503 TGF-beta receptor type-1
Topological domain 148 – 503 Cytoplasmic
Domain 205 – 495 Protein kinase
Helix 485 – 497



Literature citations
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2.
Loeys B.L.; Chen J.; Neptune E.R.; Judge D.P.; Podowski M.; Holm T.; Meyers J.; Leitch C.C.; Katsanis N.; Sharifi N.; Xu F.L.; Myers L.A.; Spevak P.J.; Cameron D.E.; De Backer J.F.; Hellemans J.; Chen Y.; Davis E.C.; Webb C.L.; Kress W.; Coucke P.J.; Rifkin D.B.; De Paepe A.M.; Dietz H.C.;
Nat. Genet. 37:275-281(2005)
Cited for: VARIANTS LDS1 ILE-200; ARG-318; GLY-400 AND PRO-487; Aneurysm syndromes caused by mutations in the TGF-beta receptor.
Loeys B.L.; Schwarze U.; Holm T.; Callewaert B.L.; Thomas G.H.; Pannu H.; De Backer J.F.; Oswald G.L.; Symoens S.; Manouvrier S.; Roberts A.E.; Faravelli F.; Greco M.A.; Pyeritz R.E.; Milewicz D.M.; Coucke P.J.; Cameron D.E.; Braverman A.C.; Byers P.H.; De Paepe A.M.; Dietz H.C.;
N. Engl. J. Med. 355:788-798(2006)
Cited for: VARIANTS LDS1 GLU-232; TRP-487; PRO-487 AND GLN-487;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.